Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second‐line pembrolizumab in patients with non‐small‐cell lung cancer | Zendy

Petrova M. P. | Zendy; Donev I. S. | Zendy; Radanova M. A. | Zendy; Eneva M. I. | Zendy; Dimitrova E. G. | Zendy; Valchev G. N. | Zendy; Minchev V. T. | Zendy; Taushanova M. S. | Zendy; Boneva M. V. | Zendy; Karanikolova T. S. | Zendy; Gencheva R. B. | Zendy; Zhbantov G. A. | Zendy; Ivanova A. I. | Zendy; Timcheva C. V. | Zendy; P.Pavlov B. | Zendy; Megdanova V. G. | Zendy; Robev B. S. | Zendy; Conev N. V. | Zendy

Open Access

Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second‐line pembrolizumab in patients with non‐small‐cell lung cancer

Author(s) -

Petrova M. P.,

Donev I. S.,

Radanova M. A.,

Eneva M. I.,

Dimitrova E. G.,

Valchev G. N.,

Minchev V. T.,

Taushanova M. S.,

Boneva M. V.,

Karanikolova T. S.,

Gencheva R. B.,

Zhbantov G. A.,

Ivanova A. I.,

Timcheva C. V.,

P.Pavlov B.,

Megdanova V. G.,

Robev B. S.,

Conev N. V.

Publication year - 2020

Publication title -

clinical & experimental immunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.329

H-Index - 135

eISSN - 1365-2249

pISSN - 0009-9104

DOI - 10.1111/cei.13505

Subject(s) - pembrolizumab , medicine , lung cancer , odds ratio , confidence interval , immunotherapy , chemotherapy , cancer , gastroenterology , retrospective cohort study , sarcopenia , oncology , immunology

The current study suggests that a high pretreatment neutrophil to lymphocyte ratio and presence of low muscle mass (sarcopenia) are potential risk factors for the development of hyperprogressive disease and shorter survival upon treatment with Pembrolizumab.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research